This process aims to be completely transparent , to enable faster patient access to oncology treatme...
Read moreTopics covered include are payers helping or hindering biosimilar market access as well as can MCDA ...
Read moreMulti-criteria decision analysis (MCDA) is a potentially useful tool that can be used to support dec...
Read moreNICE has recently published a consultation on changes to its appraisal process to "fast track" some ...
Read moreBiosimilars have the potential to be considered comparable to generics and offer healthcare benefits...
Read moreNICE propose to charge to conduct single technology appraisals from May 2017.
Read moreEnabling physicians to identify patients who are most likely to respond to treatment thereby achievi...
Read morePharma companies must start preparing its NICE submission at the time of making the regulatory subm...
Read moreTopics include our perspectives on an EU commission report on how international reference pricing ca...
Read moreFrom July 2016 NICE will gain decision power by saying yes, no or maybe to cancer drugs entering the...
Read more